Atherosclerosis, Caveolae and Caveolin-1

  • Stephanos Pavlides
  • Jorge L. Gutierrez-Pajares
  • Christiane Danilo
  • Michael P. Lisanti
  • Philippe G. FrankEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 729)


Atherosclerosis is a disease of the blood vessel characterized by the development of an arterial occlusion containing lipid and cellular deposits. Caveolae are 50–100 nm cell surface plasma membrane invaginations that are believed to play an important role in the regulation of cellular signaling and transport of molecules among others. These organelles are enriched in sphingolipids and cholesterol and are characterized by the presence of the protein caveolin-1. Caveolin-1 and caveolae are present in most of the cells involved in the development of atherosclerosis. The current literature suggests a rather complex role for caveolin-1 in this disease, with evidence of either pro- or anti-atherogenic functions depending on the cell type examined. In the present chapter, the various roles of caveolae and caveolin-1 in the development of atherosclerosis are examined.


Atherosclerosis Development Striate Muscle Cell Smooth Muscle Cell Migration Macrophage Apoptosis Vascular Smooth Muscle Cell Migration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lusis AJ. Atherosclerosis. Nature 2000; 407(6801):233–241.PubMedGoogle Scholar
  2. 2.
    Castelli WP, Doyle JT, Gordon T et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55(5):767–772.PubMedGoogle Scholar
  3. 3.
    Williams KJ, Tabas I. Lipoprotein retention—and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005; 25(8):1536–1540.Google Scholar
  4. 4.
    Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2):S419–420.Google Scholar
  5. 5.
    Gustafsson M, Boren J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004; 15(5):505–514.PubMedGoogle Scholar
  6. 6.
    Hogg N, Landis RC. Adhesion molecules in cell interactions. Curr Opin Immunol 1993; 5(3):383–390.PubMedGoogle Scholar
  7. 7.
    Lasky LA, Singer MS, Dowbenko D et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 1992; 69(6):927–938.PubMedGoogle Scholar
  8. 8.
    Song C, Hsu K, Yamen E et al. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009; 207(2):374–383.PubMedGoogle Scholar
  9. 9.
    Tabas I, Seimon T, Timmins J et a1. Macrophage apoptosis in advanced atherosclerosis. Ann N Y Acad Sci 2009; 1173(Suppl 1):E40–45.Google Scholar
  10. 10.
    Bhakdi S, Dorweiler B, Kirchmann R et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182(6):1959–1971.PubMedGoogle Scholar
  11. 11.
    Goldstein JL, Ho YK, Basu SK et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76(1):333–337.PubMedGoogle Scholar
  12. 12.
    Suzuki H, Kurihara Y, Takeya M et al. The multiple roles of macrophage scavenger receptors (MSR) in vivo: resistance to atherosclerosis and susceptibility to infection in MSR knockout mice. J Atheroscler Thromb 1997; 4(1):1–11.PubMedGoogle Scholar
  13. 13.
    Febbraio M, Podrez EA, Smith JD et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105:1049–1056.PubMedGoogle Scholar
  14. 14.
    Kockx MM, De Meyer GR, Muhring J et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97(23):2307–2315.PubMedGoogle Scholar
  15. 15.
    Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000; 45(3):736–746.PubMedGoogle Scholar
  16. 16.
    Tabas I, Marathe S, Keesler GA et al. Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis. J Biol Chem 1996; 271(37):22773–22781.PubMedGoogle Scholar
  17. 17.
    Warner GJ, Stoudt G, Bamberger M et al. Cell toxicity induced by inhibition of acyl coenzyme A: cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem 1995; 270(11):5772–5778.PubMedGoogle Scholar
  18. 18.
    Mitchinson MJ, Hardwick SJ, Bennett MR. Cell death in atherosclerotic plaques. Curr Opin Lipidol 1996; 7(5):324–329.PubMedGoogle Scholar
  19. 19.
    Chin BY, Petrache I, Choi AM et al. Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 1999; 274(16):11362–11368.PubMedGoogle Scholar
  20. 20.
    Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22(9):1370–1380.PubMedGoogle Scholar
  21. 21.
    Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res 2010; 106(1):58–67.PubMedGoogle Scholar
  22. 22.
    Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25(11):2255–2264.PubMedGoogle Scholar
  23. 23.
    Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 1994; 14(1):141–147.PubMedGoogle Scholar
  24. 24.
    Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104(4):503–516.PubMedGoogle Scholar
  25. 25.
    Smithies O, Maeda N. Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proc Natl Acad Sci USA 1995; 92(12):5266–5272.PubMedGoogle Scholar
  26. 26.
    Breslow JL. Mouse models of atherosclerosis. Science 1996; 272(5262):685–688.PubMedGoogle Scholar
  27. 27.
    Yamada E. The fine structure of the renal glomerulus of the mouse. J Histochem Cytochem 1955; 3(4):309.PubMedGoogle Scholar
  28. 28.
    Palade GE. Fine structure of blood capillaries. J Appl Physics 1953; 24:1424.Google Scholar
  29. 29.
    Rietveld A, Simons K. The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochim Biophys Acta 1998; 1376(3):467–479.PubMedGoogle Scholar
  30. 30.
    Waugh MG, Hsuan JJ. Preparation of membrane rafts. Methods Mol Biol 2009; 462:403–414.PubMedGoogle Scholar
  31. 31.
    Sargiacomo M, Sudol M, Tang Z et al. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993; 122(4):789–807.PubMedGoogle Scholar
  32. 32.
    Lisanti MP, Tang Z, Scherer PE et al. Caveolae purification and glycosylphosphatidylinositol-linked protein sorting in polarized epithelia. Methods Enzymol 1995; 250:655–668.PubMedGoogle Scholar
  33. 33.
    Lisanti MP, Scherer PE, Vidugiriene J et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 1994; 126(1):111–126.PubMedGoogle Scholar
  34. 34.
    Cohen AW, Razani B, Schubert W et al. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 2004; 53(5):1261–1270.PubMedGoogle Scholar
  35. 35.
    Chang WJ, Ying Y, Rothberg KG et al. Purification and characterization of smooth muscle cell caveolae. J Cell Biol 1994; 126:127–138.PubMedGoogle Scholar
  36. 36.
    Anderson RG. The caveolae membrane system. Annu Rev Biochem 1998; 67:199–225.PubMedGoogle Scholar
  37. 37.
    Rothberg KG, Ying Y, Kamen BA et al. Cholesterol controls the clustering of the glycophopholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol 1990; 111:2931–2938.PubMedGoogle Scholar
  38. 38.
    Rothberg KG, Heuser JE, Donzell WC et al. Caveolin, a protein component of caveolae membrane coats. Cell 1992; 68(4):673–682.PubMedGoogle Scholar
  39. 39.
    Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004; 5(3):214.PubMedGoogle Scholar
  40. 40.
    Bouras T, Lisanti MP, Pestell RG. Caveolin-1 in breast cancer. Cancer Biol Ther 2004; 3(10):931–941.PubMedGoogle Scholar
  41. 41.
    Razani B, Lisanti MP. Caveolins and caveolae: molecular and functional relationships. Exp Cell Res 2001; 271(1):36–44.PubMedGoogle Scholar
  42. 42.
    Razani B, Engelman JA, Wang XB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276(41):38121–38138.PubMedGoogle Scholar
  43. 43.
    Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293(5539):2449–2452.PubMedGoogle Scholar
  44. 44.
    Dupree P, Parton RG, Raposo G et al. Caveolae and sorting in the trans-Golgi network of epithelial cells. EMBO J 1993; 12(4):1597–1605.PubMedGoogle Scholar
  45. 45.
    Kurzchalia T, Dupree P, Parton RG et al. VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 1992; 118:1003–1014.PubMedGoogle Scholar
  46. 46.
    Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 1989; 264(34):20163–20166.Google Scholar
  47. 47.
    Sargiacomo M, Scherer PE, Tang Z et al. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA 1995; 92(20):9407–9411.PubMedGoogle Scholar
  48. 48.
    Tang Z, Scherer PE, Okamoto T et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996; 271(4):2255–2261.PubMedGoogle Scholar
  49. 49.
    Scherer PE, Tang Z, Chun M et al. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 1995; 270(27):16395–16401.PubMedGoogle Scholar
  50. 50.
    Llaverias G, Vazquez-Carrera M, Sanchez RM et al. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res 2004; 45(11):2015–2024.PubMedGoogle Scholar
  51. 51.
    Gargalovic P, Dory L. Cellular apoptosis is associated with increased caveolin-1 expression in macrophages. J Lipid Res 2003; 44(9):1622–1632.PubMedGoogle Scholar
  52. 52.
    Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA 1997; 94(8):3753–3758.PubMedGoogle Scholar
  53. 53.
    Uittenbogaard A, Ying Y, Smart EJ. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem 1998; 273(11):6525–6532.PubMedGoogle Scholar
  54. 54.
    Uittenbogaard A, Smart EJ. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation and rapid transport of cholesterol to caveolae. J Biol Chem 2000; 275(33):25595–25599.PubMedGoogle Scholar
  55. 55.
    Murata M, Peranen J, Schreiner R et al. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 1995; 92(22):10339–10343.PubMedGoogle Scholar
  56. 56.
    Monier S, Dietzen DJ, Hastings WR et al. Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol. FEBS Lett 1996; 388(2-3):143–149.PubMedGoogle Scholar
  57. 57.
    Williams TM, Medina F, Badano I et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279(49):51630–51646.PubMedGoogle Scholar
  58. 58.
    Cohen AW, Hnasko R, Schubert W et al. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84(4):1341–1379.PubMedGoogle Scholar
  59. 59.
    Liu P, Ying YS, Anderson RGW. PDGF activates MAP kinase in isolated caveolae. Proc Natl Acad Sci USA 1997; 94:13666–13670.PubMedGoogle Scholar
  60. 60.
    Lisanti MP, Scherer P, Tang ZL et al. Caveolae, caveolin and caveolin-rich membrane domains: A signalling hypothesis. Trends Cell Biol 1994; 4:231–235.PubMedGoogle Scholar
  61. 61.
    Frank PG, Lisanti MP. Role of Caveolin-1 and Caveolae in Atherosclerotic Disease States: Atheroma Formation and Neointimal Hyperplasia. Curr Opin Lipidol 2004; In press.Google Scholar
  62. 62.
    Frank PG, Lee H, Park DS et al. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24(1):98–105.PubMedGoogle Scholar
  63. 63.
    Frank PG, Pavlides S, Cheung MW et al. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008; 295(1):C242–248.Google Scholar
  64. 64.
    Ghitescu L, Fixman A, Simonescu M et al. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: Recepotor-mediated transcytosis. J Cell Biol 1986; 102:1304–1311.PubMedGoogle Scholar
  65. 65.
    Soda R, Tavassoli M. Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow. J Ultrastruct Res 1984; 88(1):18–29.PubMedGoogle Scholar
  66. 66.
    Schubert W, Frank PG, Woodman SE et al. Microvascular hyperpermeability in caveolin-1 (−/−) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 2002; 277(42):40091–40098.PubMedGoogle Scholar
  67. 67.
    Schubert W, Frank PG, Razani B et al. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001; 276(52):48619–48622.PubMedGoogle Scholar
  68. 68.
    Palade GE, Bruns RR. Structural modification of plasmalemma vesicles. J Cell Biol 1968; 37:633–649.PubMedGoogle Scholar
  69. 69.
    Vasile E, Simionescu M, Simionescu N. Visualization of the binding, endocytosis and transcytosis of low density lipoprotein in the arterial endothelium in situ. J Cell Biol 1983; 96:1677–1689.PubMedGoogle Scholar
  70. 70.
    Simionescu N, Simionescu M, Palade GE. Open junctions in the endothelium of the postcapillary venules of the diaphragm. J Cell Biol 1978; 79(1):27–44.PubMedGoogle Scholar
  71. 71.
    Dehouck B, Fenart L, Dehouck MP et al. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997; 138(4):877–889.PubMedGoogle Scholar
  72. 72.
    Balazs Z, Panzenboeck U, Hammer A et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004; 89(4):939–950.PubMedGoogle Scholar
  73. 73.
    Yeh DC, Duncan JA, Yamashita S et al. Depalmitoylation of endothelial nitric-oxide synthase by acyl-protein thioesterase 1 is potentiated by Ca(2?)-calmodulin. J Biol Chem 1999; 274(46):33148–33154.PubMedGoogle Scholar
  74. 74.
    Robinson LJ, Michel T. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc Natl Acad Sci USA 1995; 92(25):11776–11780.PubMedGoogle Scholar
  75. 75.
    Busconi L, Michel T. Endothelial nitric oxide synthase. N-terminal myristoylation determines subcellular localization. J Biol Chem1993; 268(12):8410–8413.PubMedGoogle Scholar
  76. 76.
    Michel JB, Feron O, Sase K et al. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997; 272(41):25907–25912.PubMedGoogle Scholar
  77. 77.
    Feron O, Belhassen L, Kobzik L et al. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996; 271(37):22810–22814.PubMedGoogle Scholar
  78. 78.
    Michel T, Feron O. Nitric oxide synthases: which, where, how and why? J Clin Invest 1997; 100(9):2146–2152.PubMedGoogle Scholar
  79. 79.
    Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113(13):1708–1714.PubMedGoogle Scholar
  80. 80.
    Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002; 64:749–774.PubMedGoogle Scholar
  81. 81.
    Gimbrone MA Jr, Topper JN, Nagel T et al. Endothelial dysfunction, hemodynamic forces and atherogenesis. Ann N Y Acad Sci 2000; 902:230–239.PubMedGoogle Scholar
  82. 82.
    Petruzzelli L, Takami M, Humes HD. Structure and function of cell adhesion molecules. Am J Med 1999; 106(4):467–476.PubMedGoogle Scholar
  83. 83.
    O’ Brien KD, Allen MD, McDonald TO et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92(2):945–951.PubMedGoogle Scholar
  84. 84.
    Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001; 107(10):1209–1210.PubMedGoogle Scholar
  85. 85.
    Dansky HM, Barlow CB, Lominska C et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 2001; 21(10):1662–1667.PubMedGoogle Scholar
  86. 86.
    Fernandez-Hernando C, Yu J, Suarez Y et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab 2009; 10(1):48–54.PubMedGoogle Scholar
  87. 87.
    Frank PG. Endothelial Caveolae and Caveolin-1 as Key Regulators of Atherosclerosis. Am J Pathol 2010.Google Scholar
  88. 88.
    Oxhorn BC, Buxton IL. Caveolar compartmentation of caspase-3 in cardiac endothelial cells. Cell Signal 2003; 15(5):489–496.PubMedGoogle Scholar
  89. 89.
    Peterson TE, Guicciardi ME, Gulati R et al. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 2003; 23(9):1521–1527.PubMedGoogle Scholar
  90. 90.
    Liu J, Lee P, Galbiati F et al. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 2001; 280(4):C823–835.Google Scholar
  91. 91.
    Ko YG, Lee JS, Kang YS et al. TNF-alpha-mediated apoptosis is initiated in caveolae-like domains. J Immunol 1999; 162(12):7217–7223.PubMedGoogle Scholar
  92. 92.
    Liu J, Thewke DP, Su YR et al. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2005; 25(1):174–179.PubMedGoogle Scholar
  93. 93.
    Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol 2003; 23(9):1608–1614.PubMedGoogle Scholar
  94. 94.
    Arai S, Shelton JM, Chen M et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab 2005; 1(3):201–213.PubMedGoogle Scholar
  95. 95.
    Frank PG, Cheung MW, Pavlides S et al. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am J Physiol Heart Circ Physiol 2006; 291(2):H677–686.Google Scholar
  96. 96.
    Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116(12):3090–3100.PubMedGoogle Scholar
  97. 97.
    Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ 2004; 11 Suppl 1:S12–16.Google Scholar
  98. 98.
    Chang TY, Chang CC, Lin S et al. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and-2. Curr Opin Lipidol 2001; 12(3):289–296.PubMedGoogle Scholar
  99. 99.
    Cui D, Thorp E, Li Y et al. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol 2007; 82(5):1040–1050.PubMedGoogle Scholar
  100. 100.
    Savill J, Dransfield I, Gregory C et al. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2(12):965–975.PubMedGoogle Scholar
  101. 101.
    Schrijvers DM, De Meyer GR, Herman AG et al. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 2007; 73(3):470–480.PubMedGoogle Scholar
  102. 102.
    Li J, Scherl A, Medina F et al. Impaired phagocytosis in caveolin-1 deficient macrophages. Cell Cycle 2005; 4(11):1599–1607.PubMedGoogle Scholar
  103. 103.
    Hegyi L, Hardwick SJ, Siow RC et al. Macrophage death and the role of apoptosis in human atherosclerosis. J Hematother Stem Cell Res 2001; 10(1):27–42.PubMedGoogle Scholar
  104. 104.
    Fais S. Cannibalism: a way to feed on metastatic tumors. Cancer Lett 2007; 258(2):155–164.PubMedGoogle Scholar
  105. 105.
    Chidlow JH Jr, Sessa WC. Caveolae, caveolins and cavins: complex control of cellular signalling and inflammation. Cardiovasc Res 2010; 86(2):219–225.PubMedGoogle Scholar
  106. 106.
    Wang XM, Kim HP, Song R et al. Caveolin-1 Confers Anti-Inflammatory Effects in Murine Macrophages via the MKK3/p38 MAPK Pathway. Am J Respir Cell Mol Biol 2005.Google Scholar
  107. 107.
    Imai H, Lee KT, Pastori S et al. Atherosclerosis in rabbits. Architectural and subcellular alterations of smooth muscle cells of aortas in response to hyperlipemia. Exp Mol Pathol 1966; 5(3):273–310.PubMedGoogle Scholar
  108. 108.
    Thomas WA, Florentin RA, Nam SC et al. Alterations in population dynamics of arterial smooth muscle cells during atherogenesis. I. Activation of interphase cells in cholesterol-fed swine prior to gross atherosclerosis demonstrated by “postpulse-salvage labeling”. Exp Mol Pathol 1971; 15(2):245–267.PubMedGoogle Scholar
  109. 109.
    Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180(93):1332–1339.PubMedGoogle Scholar
  110. 110.
    Goldfischer S, Schiller B, Wolinsky H. Lipid accumulation in smooth muscle cell lysosomes im primate atherosclerosis. Am J Pathol 1975; 78(3):497–504.PubMedGoogle Scholar
  111. 111.
    Aqel NM, Ball RY, Waldmann H et al. Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol 1985; 146(3):197–204.PubMedGoogle Scholar
  112. 112.
    Thyberg J, Nilsson J, Palmberg L et al. Adult human arterial smooth muscle cells in primary culture. Modulation from contractile to synthetic phenotype. Cell Tissue Res 1985; 239(1):69–74.PubMedGoogle Scholar
  113. 113.
    Sjolund M, Madsen K, von der Mark K et al. Phenotype modulation in primary cultures of smooth-muscle cells from rat aorta. Synthesis of collagen and elastin. Differentiation 1986; 32(2):173–180.PubMedGoogle Scholar
  114. 114.
    Hedin U, Thyberg J. Plasma fibronectin promotes modulation of arterial smooth-muscle cells from contractile to synthetic phenotype. Differentiation 1987; 33(3):239–246.PubMedGoogle Scholar
  115. 115.
    Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol 1985; 42(2):139–162.PubMedGoogle Scholar
  116. 116.
    Yerneni KK, Bai W, Khan BV et al. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999; 48(4):855–864.PubMedGoogle Scholar
  117. 117.
    Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med 2002; 9(1):85–89.PubMedGoogle Scholar
  118. 118.
    Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005; 85(1):9–23.PubMedGoogle Scholar
  119. 119.
    Tani E, Yamagata S, Ito Y. Cell membrane structure of vascular smooth muscle of circle of Willis. Cell Tissue Res 1977; 179(1):131–142.PubMedGoogle Scholar
  120. 120.
    Peterson TE, Kleppe LS, Caplice NM et al. The regulation of caveolin expression and localization by serum and heparin in vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 265(3):722–727.PubMedGoogle Scholar
  121. 121.
    Thyberg J. Differences in caveolae dynamics in vascular smooth muscle cells of different phenotypes. Lab Invest 2000; 80(6):915–929.PubMedGoogle Scholar
  122. 122.
    Song KS, Scherer PE, Tang Z et al. Expression of caveolin-3 in skeletal, cardiac and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and cofractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 1996; 271(25):15160–15165.PubMedGoogle Scholar
  123. 123.
    Doyle DD, Upshaw-Earley J, Bell E et al. Expression of caveolin-3 in rat aortic vascular smooth muscle cells is determined by developmental state. Biochem Biophys Res Commun 2003; 304(1):22–25.PubMedGoogle Scholar
  124. 124.
    Ishizaka N, Griendling KK, Lassegue B et al. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998; 32(3):459–466.PubMedGoogle Scholar
  125. 125.
    Galbiati F, Engelman JA, Volonte D et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex and t-tubule abnormalities. J Biol Chem 2001; 276(24):21425–21433.PubMedGoogle Scholar
  126. 126.
    Park DS, Woodman SE, Schubert W et al. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and nonmuscle caveolae and develop a severe cardiomyopathic phenotype. Am J Pathol 2002; 160(6):2207–2217.PubMedGoogle Scholar
  127. 127.
    Schwencke C, Schmeisser A, Walter C et al. Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res 2005; 68(1):128–135.PubMedGoogle Scholar
  128. 128.
    Cho WJ, Daniel EE. Colocalization between caveolin isoforms in the intestinal smooth muscle and interstitial cells of Cajal of the Cav1(+/+) and Cav1(−/−) mouse. Histochem Cell Biol 2006; 126(1):9–16.PubMedGoogle Scholar
  129. 129.
    Cheng X, Jaggar JH. Genetic ablation of caveolin-1 modifies Ca2+ spark coupling in murine arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 290(6):H2309–2319.Google Scholar
  130. 130.
    Segal SS, Brett SE, Sessa WC. Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am J Physiol 1999; 277(3 Pt 2):H1167–1177.Google Scholar
  131. 131.
    Arnal JF, Dinh-Xuan AT, Pueyo M et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55(8–9):1078–1087.PubMedGoogle Scholar
  132. 132.
    Pandolfi A, Grilli A, Cilli C et al. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation. J Cell Physiol 2003; 196(2):378–385.PubMedGoogle Scholar
  133. 133.
    Cheah LS, Gwee M, Das R et al. Evidence for the existence of a constitutive nitric oxide synthase in vascular smooth muscle. Clin Exp Pharmacol Physiol 2002; 29(8):725–727.PubMedGoogle Scholar
  134. 134.
    Yu J, Bergaya S, Murata T et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest 2006; 116(5):1284–1291.PubMedGoogle Scholar
  135. 135.
    Murata T, Lin MI, Huang Y et al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 2007; 204(10):2373–2382.PubMedGoogle Scholar
  136. 136.
    Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003; 547(Pt 1):21–33.PubMedGoogle Scholar
  137. 137.
    Feron O, Dessy C, Moniotte S et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103(6):897–905.PubMedGoogle Scholar
  138. 138.
    Venema VJ, Ju H, Zou R et al. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem 1997; 272(45):28187–28190.PubMedGoogle Scholar
  139. 139.
    Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 1995; 96(1):141–149.PubMedGoogle Scholar
  140. 140.
    Newby AC, George SJ. Proliferation, migration, matrix turnover and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr Opin Cardiol 1996; 11(6):574–582.PubMedGoogle Scholar
  141. 141.
    Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 100(11 Suppl):S87–89.Google Scholar
  142. 142.
    Shimokado K, Yokota T, Kosaka C et al. Protein tyrosine kinase inhibitors inhibit both proliferation and chemotaxis of vascular smooth muscle cells. Ann N Y Acad Sci 1995; 748:171–175; discussion 175–176.PubMedGoogle Scholar
  143. 143.
    Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275(5 Pt 1):L843–851.Google Scholar
  144. 144.
    Okamoto T, Schlegel A, Scherer PE et al. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem 1998; 273(10):5419–5422.PubMedGoogle Scholar
  145. 145.
    Hulit J, Bash T, Fu M et al. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 2000; 275(28):21203–21209.PubMedGoogle Scholar
  146. 146.
    Engelman JA, Chu C, Lin A et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998; 428(3):205–211.PubMedGoogle Scholar
  147. 147.
    Capozza F, Williams TM, Schubert W et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003; 162(6):2029–2039.PubMedGoogle Scholar
  148. 148.
    Rodriguez-Feo JA, Hellings WE, Moll FL et al. Caveolin-1 influences vascular protease activity and is a potential stabilizing factor in human atherosclerotic disease. PLoS One 2008; 3(7):e2612.Google Scholar
  149. 149.
    Hassan GS, Williams TM, Frank PG et al. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration and endothelin-based signal transduction. Am J Physiol Heart Circ Physiol 2006; 290(6):H2393–2401.Google Scholar
  150. 150.
    Lavezzi AM, Ottaviani G, Matturri L. Biology of the smooth muscle cells in human atherosclerosis. Apmis 2005; 113(2):112–121.PubMedGoogle Scholar
  151. 151.
    Luo DX, Cheng J, Xiong Y et al. Static pressure drives proliferation of vascular smooth muscle cells via caveolin-1/ERK1/2 pathway. Biochem Biophys Res Commun 2010; 391(4):1693–1697.PubMedGoogle Scholar
  152. 152.
    Galbiati F, Volonte D, Engelman JA et al. Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO Journal 1998; 17:6633–6648.PubMedGoogle Scholar
  153. 153.
    Morla AO, Mogford JE. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 2000; 272(1):298–302.PubMedGoogle Scholar
  154. 154.
    Ghrib F, Brisset AC, Dupouy D et al. The expression of tissue factor and tissue factor pathway inhibitor in aortic smooth muscle cells is up-regulated in synthetic compared to contractile phenotype. Thromb Haemost 2002; 87(6):1051–1056.PubMedGoogle Scholar
  155. 155.
    Batetta B, Mulas MF, Petruzzo P et al. Opposite pattern of MDR1 and caveolin-1 gene expression in human atherosclerotic lesions and proliferating human smooth muscle cells. Cell Mol Life Sci 2001; 58(8):1113–1120.PubMedGoogle Scholar
  156. 156.
    Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17(10):2238–2244.PubMedGoogle Scholar
  157. 157.
    Sedding DG, Braun-Dullaeus RC. Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med 2006; 16(2):50–55.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Stephanos Pavlides
    • 1
  • Jorge L. Gutierrez-Pajares
    • 1
  • Christiane Danilo
    • 1
  • Michael P. Lisanti
    • 1
  • Philippe G. Frank
    • 1
    Email author
  1. 1.Departments of Cancer Biology and Stem Cell Biology and Regenerative MedicineThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations